Ristau, J.
Giesel, F. L.
Haefner, M. F.
Staudinger, F.
Lindner, T.
Merkel, A.
Schlittenhardt, J.
Kratochwil, C.
Choyke, P. L.
Herfarth, K.
Debus, J.
Haberkorn, U.
Koerber, S. A.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 31 July 2020
Revised: 17 September 2020
Accepted: 29 September 2020
First Online: 15 October 2020
Compliance with Ethical Standards
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The authors FLG, UH, CK and TL have a patent application (EP 18155420.5) for quinoline-based FAP-targeting agents for imaging and therapy in nuclear medicine. All other authors declare no potential conflicts of interest relevant to this article.
: Informed consent was obtained from all individual participants included in the study.